PHASE II-B RANDOMIZED CONTROLLED STUDY OF TISSUE PLASMIN

组织纤溶酶的 II-B 期随机对照研究

• 批准号: 3668543
• 负责人: BRUCE C MACKAY
• 金额: $ 15.43万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-06-30 至 1993-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3668543
• 关键词: cardiovascular disorder chemotherapy; clinical trials; human subject; human therapy evaluation; plasminogen activator; stroke

The specific objectives of this contract are to establish the validity of current documentation of observed early initial response to treatment of acute ischemic stroke with recombinant tissue plasminogen activator (rt-PA) and to establish time limits for delivering such treatment. The objectives will be accomplished by completing a Phase II-B randomized controlled clinical study of rt-PA for acute ischemic stroke.

本合同的具体目标是建立有效性 观察到的早期初始治疗反应的当前记录 重组组织型纤溶酶原激活剂治疗急性缺血性卒中 （rt-PA），并确定提供此类治疗的时限。 的 目标将通过完成II-B期随机 rt-PA治疗急性缺血性脑卒中的临床对照研究